Frequently Asked Questions
What is iCo Therapeutics’ Business?
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications.
What are iCo’s Products?
iCo has exclusive worldwide rights to two products, iCo-007, in Phase I for the treatment of Diabetic Macular Edema, and iCo-008, a product with Phase II clinical history to be developed for severe ocular allergies and Wet Age Related Macular Degeneration. iCo Therapeutics has an exclusive option to license iCo-009, a oral reformulation of Amphotericin B for sight and life threatening diseases. iCo-009 also represents a new drug delivery technology with the potential to reprofile other IV administered drugs to the oral route of administration.
What exchange is iCo traded on, and what is the symbol?
iCo is traded on the Toronto Stock Exchange (Venture) under the symbol ICO .
Where can I access iCo’s financial statements?
Please visit SEDAR.
When was iCo Therapeutics founded?
iCo Therapeutics was founded in 2005 by Andrew Rae, John Clement and John Meekison.
When is iCo’s fiscal year-end date?
iCo Therapeutics operates on a fiscal year ending December 31.
Who is iCo’s Transfer Agent?
Communication concerning transfer requirements, lost certificates, change of address and other similar inquiries should be addressed to our transfer agent:
Computershare Investor Services Inc.
In person delivery:
510 Burrard Street,